{'fraction_non_alphanumeric': 0.031746031746031744, 'fraction_numerical': 0.020202020202020204, 'mean_word_length': 4.852320675105485, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic effectiveness & safety of favipiravir in COVID‐19 patients with risk factors for mortality: Clinical practice experience from India

bin and tissue oxygenation in severe hypoxemia and tissue hypoxia. It has also exhibited anti-inflammatory effects on inflammasomes, proinflammatory and inflammatory cytokines, and chemokines. With the given physiologic benefits of HBOT, this study aims to identify the effect of HBOT among severe COVID-19 patients. Methods: Several trials using HBOT among COVID-19 patients were analyzed in this meta-analysis. The treatment group utilized HBOT while standard of care was used in the control group. The primary outcome is the incidence of inpatient mortality. The secondary outcome is the incidence of progression to invasive mechanical ventilation (IMV). Results and Conclusions: 3 trials were included in this study. The incidence of mortality was 12% in the HBOT group and 26% in the standard of care group (P = 0.02). Progression to IMV was also lower in the HBOT with 13% compared to the control group with 46% (P = 0.003). HBOT for viral infections has been documented even before the COVID-19 pandemic. In this study, the use of HBOT among severe COVID-19 patients have shown favorable results. HBOT is a promising alternative or additional treatment for COVID-19. Larger trials are needed to better demonstrate the benefit of HBOT.